+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Companion Animal Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030

  • PDF Icon

    Report

  • 150 Pages
  • August 2024
  • Region: Global
  • Lucintel
  • ID: 6007043
The global companion animal vaccine market is expected to reach an estimated $4.8 billion by 2030 with a CAGR of 6.3% from 2024 to 2030. The major drivers for this market are the rising awareness about importance of pet vaccination, growing cases of zoonotic diseases, and increasing interest for pet ownership in the world.

The future of the global companion animal vaccine market looks promising with opportunities in the hospital & clinic and research institute markets.
  • Canines will remain the largest segment due to increasing awareness of the importance of this vaccination among dog owners for protecting their pets from serious diseases.
  • Within this market, hospital & clinics are expected to witness the highest growth over the forecast period. North America will remain the largest region due to high pet ownership rates and increasing awareness of the importance of pet vaccination among the population in the region.

Emerging Trends in the Companion Animal Vaccine Market

The market for Companion Animal Vaccines is evolving at a rapid pace due to technological advances, changing consumer preferences, and new regulatory environments. Future trends are shaping up this market which prompt innovations in vaccine development, distribution, and administration.
  • Personalized Vaccines: Genetic profiling has enabled the development of personalized vaccines tailored to individual pets’ requirements which is making this concept increasingly popular. This trend is particularly pronounced in countries like Japan and the USA where pet owners seek bespoke healthcare solutions for their animals. These vaccines offer increased efficacy with minimum side effects hence becoming the preferred choice.
  • DNA and RNA-Based Vaccines: The use of DNA and RNA as vaccines is increasing because they offer quick protection against a broad range of diseases. These kinds of vaccines are especially beneficial in fighting emerging infectious diseases. Many companies are developing these cutting-edge vaccines in the US and European markets.
  • Increasing Focus on Zoonotic Disease Prevention: The emphasis on vaccines, which are not only designed to protect pets from infectious diseases but also reduce the risk of transmitting them to humans, is rising as zoonoses become more prevalent. In places like Germany where animal health is an integral part of public health, this trend is picking up. These vaccines would also be central to integrated health strategies.
  • Expanding Vaccine Accessibility: There is a growing momentum towards improving vaccine access globally, particularly in emerging economies such as India and China. This has increased vaccination rates and improved overall animal health outcomes by making vaccines affordable and widely available through collaborations between businesses and governments.
  • Biotechnology Integration: Incorporating advanced biotechnology into vaccine development is transforming the market. Scientists have started using technologies such as CRISPR and synthetic biology that create better yet safer vaccines. New generations of vaccines with greater effectiveness, safety needs addressed during their design process, and quick efficient production are expected to result from this trend.
These developments will reshape how vaccines are formulated, spread out, and put into use as a result of improving companion animals’ health outlooks globally.

The future of the companion animal vaccine market is being pushed by these trends towards more efficient, individualized, and accessible vaccines.

Recent Developments in the Companion Animal Vaccine Market

The growth and evolution of the companion animal vaccine market have been driven by several important developments. These improvements indicate an increasing need for new and efficient vaccines as well as the attempts to maximize global access and efficacy.
  • Innovative DNA-based Vaccines: Recent advances in DNA-based vaccines are making great strides toward broader coverages with reduced doses. Designed to fight various diseases, these vaccines offer more effective and targeted immunization options for pet animals.
  • Global Manufacturing Expansion: Vaccine producers are investing in new production plants, especially in developing countries including China and India that help increase the supply of vaccines. The expansion is crucial in addressing the increasing demand for vaccines worldwide as well as ensuring their availability on time.
  • Collaborations for Zoonotic Disease Prevention: Joint ventures between veterinary research centers and pharmaceutical firms have resulted in the development of vaccines against zoonotic diseases. These vaccines serve to protect both pets and humans, which reflects a growing focus on connected public health approaches.
  • Low-Cost Immunization Plan: Some corporations are introducing cheap vaccines to improve immunization rates, especially in the developing world. These market initiatives are backed up by public health programs whose main objective is to sensitize the public to the importance of pet vaccination hence reducing this market's health risks.
  • Individualised Vaccine Production: In Japan and other highly-developed markets personal vaccines have become preferable, leading to research on breed or individually tailored vaccine versions. This is because they are more effective and meet the distinct healthcare needs of pets, thus being embraced by pet owners.
These trends combine to shape the companion animal vaccine market by fostering innovative ideas, extending prominence globally, and increasing vaccines’ overall efficiency along with availability. Henceforth, this will influence what will occur concretely in terms of future potential demand for companion animal healthcare services as far as its improvement is concerned.

Strategic Growth Opportunities for Companion Animal Vaccine Market

Several strategic growth opportunities are available in the companion animal vaccine market, especially in certain key application segments. These arise from advancements in vaccine technology, increased pet ownership, and a growing global animal health focus.
  • Disease-Specific Vaccines: The development of vaccines targeting specific diseases characterized by their prevalence in particular geographical areas represents a significant opportunity for growth. Companies can concentrate on making vaccines for diseases that are hyper-endemic, thereby providing custom-made solutions that successfully address local health challenges.
  • Biotechnology-Driven Vaccine Development: The incorporation of biotechnology into vaccine development such as CRISPR and synthetic biology is opening up new ways to produce more effective and safer vaccines. In this area, companies have the potential to innovate and gain market share by providing cutting-edge vaccines that meet the changing demands of pet owners.
  • Expansion in Emerging Markets: Growing numbers of pets’ owners coupled with rising demand for quality veterinary services make emerging markets like India and China attractive for investment. Those companies that establish local production facilities and distribution networks within these markets will have access to the high-growth opportunities they offer.
  • Online and Direct-to-Consumer Sales: The rise of online platforms and direct-to-consumer sales channels is creating new opportunities for vaccine distribution. Companies that leverage e-commerce and digital marketing can reach a wider audience, especially in places where veterinary services are limited.
  • Preventive Healthcare Packages: Preventive healthcare package options that include vaccines, routine check-ups, and other basic services are on the rise. These packages make it easier for pet owners to get the medical care they need on a regular basis including vaccination among others which will eventually lead to better health for all animals.
Strategic growth opportunities like innovation, market expansion, accessibility of vaccines have changed the marketplace for Companion Animal Vaccines. Taking advantage of these opportunities will put businesses at an advantageous position in this changing industry.

Companion Animal Vaccine Market Drivers and Challenges

Key drivers that shape the companion animal vaccine market include; Technological innovation, increased pet ownership, and an increase in awareness of animal health. However, there are also hurdles such as regulatory compliance barriers, high research and development costs, and some pet owners who show hesitance towards vaccines. Taken together, these elements affect what happens in the marketplace.

The factors responsible for driving the companion animal vaccine market include:

  • 1. Technological Innovation: Biotechnology advances such as DNA and RNA-based vaccines have led to the production of more efficient targeted vaccines resulting in improved health outcomes for pets thereby expanding the market reach.
  • 2. Increasing Pet Ownership: The higher incidence of pet ownership particularly in cities is driving up demand for companion animal vaccines so that they can ensure their pets’ well-being is taken care of.
  • 3. Growing Awareness of Animal Health: Informed people have a better vaccination rate due to their knowledge about diseases prevention by vaccination especially among developed markets where healthcare literacy levels are high among other reasons.
  • 4. Government Support and Regulations: In emerging markets, vaccines are being developed and distributed with the help of supportive government policies and simplified regulatory processes.
  • 5. Rise of Zoonotic Diseases: The increasing prevalence of zoonotic diseases has resulted in a demand for vaccines that address both animals and humans simultaneously.

Challenges in the companion animal vaccine market are:

  • 1. Regulatory Hurdles: Navigating complex and varying regulatory environments across different regions can delay vaccine approvals and market entry; this challenge may limit vaccine companies.
  • 2. High R&D Costs: High R&D costs, especially for innovative vaccines, can hinder entry into a market and curtail competition from smaller firms.
  • 3. Vaccine Hesitancy: Safety concerns, side effects, or false information prevent some pet owners from vaccinating their pets thus hindering market growth.
These drivers along with the challenges delineate how the companion animal vaccine market is evolving. There are numerous opportunities associated with technology advancements as well as increasing demand but overcoming economic barriers to regulation will be key if this industry is to continue experiencing growth.

List of Companion Animal Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies companion animal vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base.

Some of the companion animal vaccine companies profiled in this report include:

  • Elanco
  • Boehringer Ingelheim International
  • Intervet
  • Zoetis Services
  • Bioveta
  • Sanofi
  • Bayer
  • Heska
  • Virbac
  • Hester Biosciences

Companion Animal Vaccine by Segment

The study includes a forecast for the global companion animal vaccine by product type, species type, end use, and region.

By Product Type [Analysis by Value from 2018 to 2030]:

  • Attenuated Live
  • Conjugate
  • Inactivated
  • Subunit
  • Toxoid
  • DNA
  • Recombinant

By Species Type [Analysis by Value from 2018 to 2030]:

  • Canine
  • Avian
  • Feline
  • Equine

By End Use [Analysis by Value from 2018 to 2030]:

  • Hospitals & Clinics
  • Research Institutes
  • Others

By Region [Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia-Pacific
  • The Rest of the World

Country-wise Outlook for the Companion Animal Vaccine Market

The companion animal vaccine market has seen several improvements across the world due to increased pet ownership, innovation in vaccine technology, and growing consciousness of animal health. Moreover, this market’s growth is augmented by government initiatives and a rise in demand for safe and efficient vaccines that can protect pets from different ailments. The summary below highlights recent trends within the United States, China, Germany, India, and Japan.
  • United States: In America, there have been significant strides in developing DNA-based vaccines for pets. These companies are investing in research that aims at creating vaccines that offer wider protection with a lower number of doses. Moreover, efforts have been made to improve the distribution network to make them available on time across the country.
  • China: In China, there has been greater support from the Chinese government toward their local vaccine production. Some of these recent developments include the establishment of new manufacturing plants together with partnerships with worldwide companies aimed at improving the quality as well as accessibility of vaccines in the future. There is also a focus on expanding vaccination coverage to companion animals living in urban areas.
  • Germany: Germany has concentrated on developing vaccines against emerging zoonotic infections. Some recent collaborations between veterinary research institutes and pharmaceutical companies aim to create vaccines that not only protect animals but also reduce the risk of disease transmission to humans.
  • India: The rise in urban pet ownership has been the key driver for growth in India’s companion animal vaccine market. Some recent initiatives include affordable vaccine options being launched and awareness campaigns executed to increase vaccination rates. The government has also streamlined regulatory approvals to make new vaccines available more quickly.
  • Japan: There is a trend towards personalized vaccines for companion animals, with an emphasis on breed-specific health issues in Japan. In this regard, some of the latest developments involve advanced biotechnology that allows for the development of custom-made immunizations based on genetic profiles of individual pets and ensures better disease prevention.

Features of the Global Companion Animal Vaccine Market

  • Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
  • Segmentation Analysis: Companion animal vaccine market size by product type, species type, end use, and region in terms of value ($B).
  • Regional Analysis: Companion animal vaccine market breakdown by North America, Europe, Asia-Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different product types, species types, end uses, and regions for the companion animal vaccine market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the companion animal vaccine market.
  • Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

This report answers the following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the companion animal vaccine market by product type (attenuated live, conjugate, inactivated, subunit, toxoid, DNA, and recombinant), species type (canine, avian, feline, and equine), end use (hospitals & clinics, research institutes, and others), and region (North America, Europe, Asia-Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
2. Global Companion Animal Vaccine Market: Market Dynamics
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. Market Trends and Forecast Analysis from 2018 to 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Companion Animal Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Companion Animal Vaccine Market by Product Type
3.3.1: Attenuated Live
3.3.2: Conjugate
3.3.3: Inactivated
3.3.4: Subunit
3.3.5: Toxoid
3.3.6: DNA
3.3.7: Recombinant
3.4: Global Companion Animal Vaccine Market by Species Type
3.4.1: Canine
3.4.2: Avian
3.4.3: Feline
3.4.4: Equine
3.5: Global Companion Animal Vaccine Market by End Use
3.5.1: Hospitals & Clinics
3.5.2: Research Institutes
3.5.3: Others
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
4.1: Global Companion Animal Vaccine Market by Region
4.2: North American Companion Animal Vaccine Market
4.2.1: North American Companion Animal Vaccine Market by Species Type: Canine, Avian, Feline, and Equine
4.2.2: North American Companion Animal Vaccine Market by End Use: Hospitals & Clinics, Research Institutes, and Others
4.3: European Companion Animal Vaccine Market
4.3.1: European Companion Animal Vaccine Market by Species Type: Canine, Avian, Feline, and Equine
4.3.2: European Companion Animal Vaccine Market by End Use: Hospitals & Clinics, Research Institutes, and Others
4.4: APAC Companion Animal Vaccine Market
4.4.1: APAC Companion Animal Vaccine Market by Species Type: Canine, Avian, Feline, and Equine
4.4.2: APAC Companion Animal Vaccine Market by End Use: Hospitals & Clinics, Research Institutes, and Others
4.5: RoW Companion Animal Vaccine Market
4.5.1: RoW Companion Animal Vaccine Market by Species Type: Canine, Avian, Feline, and Equine
4.5.2: RoW Companion Animal Vaccine Market by End Use: Hospitals & Clinics, Research Institutes, and Others
5. Competitor Analysis
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. Growth Opportunities and Strategic Analysis
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Companion Animal Vaccine Market by Product Type
6.1.2: Growth Opportunities for the Global Companion Animal Vaccine Market by Species Type
6.1.3: Growth Opportunities for the Global Companion Animal Vaccine Market by End Use
6.1.4: Growth Opportunities for the Global Companion Animal Vaccine Market by Region
6.2: Emerging Trends in the Global Companion Animal Vaccine Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Companion Animal Vaccine Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Companion Animal Vaccine Market
6.3.4: Certification and Licensing
7. Company Profiles of Leading Players
7.1: Elanco
7.2: Boehringer Ingelheim International
7.3: Intervet
7.4: Zoetis Services
7.5: Bioveta
7.6: Sanofi
7.7: Bayer
7.8: Heska
7.9: Virbac
7.10: Hester Biosciences

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Elanco
  • Boehringer Ingelheim International
  • Intervet
  • Zoetis Services
  • Bioveta
  • Sanofi
  • Bayer
  • Heska
  • Virbac
  • Hester Biosciences

Methodology

The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:

  • In-depth interviews of the major players in the market
  • Detailed secondary research from competitors’ financial statements and published data
  • Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
  • A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.

Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.

Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.

 

Loading
LOADING...